Pfizer Inc. is paying Innovent Biologics Co. Ltd. $650 million up front and up to $9.85 billion in milestones, plus royalties, to collaborate across 12 early stage and de novo antibody-drug conjugates (ADCs) and multispecific antibodies for oncology.
Regulatory snapshots for biopharma and med tech in Asia-Pacific, including global submissions and approvals, and other regulatory decisions and designations: Astrazeneca, Atmo, Boehringer Ingelheim, Cornerstone Robotics, Daiichi Sankyo, Dizal, Gene Solutions, H. Lundbeck, Innocare, Optimi Health, Skia, Vanda, Zydus.
Biopharma and med-tech happenings in Asia-Pacific, including deals and partnerships, and other news in brief: Biocytogen, Bioprotect, Cgbio, Co-Diagnostics, Cosara, Cumberland, Depuy Synthes, Jiangxi Kvvit, Merz, Minmaxmedical, Olympus, Samsung Bioepis, Sciclone.
Clinical updates for biopharma and med tech in Asia-Pacific, including data readouts and publications: Ascentage, Brii, D&D, Dizal, Junshi, Kelun-Biotech, Ono, Otsuka, Sun.
The U.S. FDA approved Shionogi & Co. Ltd.’s Xocova (ensitrelvir) as the first oral post-exposure prophylactic option in the U.S. to prevent COVID-19, with the decision coming ahead of a PDUFA target date of June 16.
In 2025, China’s outbound life sciences and biopharma deals reached nearly $100 billion, about 12 times the level seen in 2021, underscoring how quickly global appetite for Chinese assets has accelerated, according to a recent report by L.E.K. Consulting.
Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for the targeted class of cancer therapeutics.
Artificial intelligence, remote monitoring and need-based innovation are beginning to reshape Australia’s medtech sector’s devices, as well as the way health care itself is delivered, according to speakers at the 2026 Ausmedtech conference in Perth May 19-20.
RSS
